Short-term Efficacy of Intravitreal Ranibizumab for Myopic Choroidal Neovascularization.
10.3341/jkos.2009.50.7.1027
- Author:
Min Hye SONG
1
;
Joon Yong KIM
;
Young Jung ROH
Author Information
1. Department of Ophthalmology and Visual Science, College of Medicine, The Catholic University of Korea, Seoul, Korea. youngjungroh@hanmail.net
- Publication Type:Original Article
- Keywords:
Choroidal neovascularization;
Pathologic myopia;
Ranibizumab (Lucentis(R))
- MeSH:
Antibodies, Monoclonal, Humanized;
Choroid;
Choroidal Neovascularization;
Eye;
Fibrosis;
Fluorescein Angiography;
Humans;
Retrospective Studies;
Visual Acuity;
Ranibizumab
- From:Journal of the Korean Ophthalmological Society
2009;50(7):1027-1034
- CountryRepublic of Korea
- Language:Korean
-
Abstract:
PURPOSE: To evaluate the effects of intravitreal ranibizumab in myopic choroidal neovascularization (CNV). METHODS: Patients who underwent intravitreal ranibizumab injection for myopic CNV, and were followed up more than 6 months, and their records were retrospectively investigated. The best corrected visual acuity, central macular thickness, and leak in fluorescein angiography were compared at baseline, and at 1, 3, and 6 months after injection. RESULTS: Twenty-one eyes of 18 patients were evaluated. The mean best corrected visual acuity (logMAR) was 1.23+/-0.65, 0.96+/- 0.40, 0.95+/-0.67, and 0.83+/-0.58 at baseline, 1, 3, and 6 months, respectively (p<0.001, p=0.006, p=0.001). The mean central macular thickness was 233.42+/-65.55 microm, 204.14+/-65.29 micrometer, and 157.76+/-71.45 microm at baseline, 3, and 6 months, respectively (p<0.001). In fluorescein angiography at 6 months after injection, regression was observed in 12 eyes, and fibrosis in 9 eyes. CONCLUSIONS: Intravitreal ranibizumab injection for myopic CNV in Korean patients appeared to be effective, resulting in regression of lesion and improvement of visual acuity.
